Drugs / ZEGRUVIRIMAT
ZEGRUVIRIMAT
also known as
VH3739937 · GSK-3739937 TOSYLATE · GSK-3739937G · GSK3739937 · VH-3739937 TOSYLATE · ZEGRUVIRIMAT TOSYLATE
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06533280 | Aug 2024 | HIV infectious disease | ViiV Healthcare | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT04493684 | Jul 2020 → Aug 2021 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06061081 | Dec 2023 → Aug 2024 | HIV infectious disease | ViiV Healthcare | Terminated | No outcome recorded Stop: Business |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZEGRUVIRIMAT | ChEMBL registry synonym — accepted as the source's own label CHEMBL6067965 ↗ |
| Known as | GSK-3739937 TOSYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL6067965 ↗ |
| Known as | GSK-3739937G | ChEMBL registry synonym — accepted as the source's own label CHEMBL6067965 ↗ |
| Known as | GSK3739937 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04493684 ↗ |
| Known as | VH-3739937 TOSYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL6067965 ↗ |
| Known as | VH3739937 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06061081 ↗ |
| Known as | ZEGRUVIRIMAT TOSYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL6067965 ↗ |
| Modality | Small molecule | — CHEMBL6067965 ↗ |
| Route | Oral | “GSK3739937 will be administered as oral suspension.” NCT04493684 ↗ |